Literature DB >> 16469581

Prostate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate.

Ernesto Lopez-Corona1, Makoto Ohori, Thomas M Wheeler, Victor E Reuter, Peter T Scardino, Michael W Kattan, James A Eastham.   

Abstract

PURPOSE: We investigated whether repeat prostate biopsies are associated with more favorable prognoses, less extensive disease or higher rates of IC in patients who are ultimately diagnosed with prostate cancer and treated with RRP.
MATERIALS AND METHODS: We examined standard clinical and pathological data on 1,357 patients treated with RRP from 1983 to 2001. In addition, we noted the rate of IC in a subgroup of 847 patients in whom tumor volume was measured.
RESULTS: Cancer was found in 1,042 patients (77%) at the first biopsy, in 227 (17%) at the second biopsy, in 59 (4%) at the third biopsy and in 29 (2%) at the fourth or later biopsy. Patients with 2 or greater biopsies had a higher rate of clinical T1c stage cancer and larger prostates than patients with only 1 biopsy (each p < 0.0001). After RRP patients with 1 biopsy had a lower rate of organ confined tumors (61% vs 75%, p < 0.0001), and a higher rate of extracapsular extension, seminal vesicle invasion, lymph node metastases and Gleason sum 7 or greater than other patients. IC was found in 10% of patients with 1 biopsy and 18% of those with 2 or greater biopsies (p = 0.018). Despite these more favorable pathological outcomes there was no difference in biochemical recurrence rate.
CONCLUSIONS: Although we found that a greater number of biopsies was related to a better pathological outcome after RRP, the number of biopsies did not predict disease recurrence. The increasing number of biopsies currently being performed, especially in patients with larger prostates, likely results in higher rates of IC.

Entities:  

Mesh:

Year:  2006        PMID: 16469581      PMCID: PMC1951512          DOI: 10.1016/S0022-5347(05)00350-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

1.  Prostate cancer detection with two sets of ten-core compared with two sets of sextant biopsies.

Authors:  K G Fink; G Hutarew; W Lumper; A Jungwirth; O Dietze; N T Schmeller
Journal:  Urology       Date:  2001-11       Impact factor: 2.649

2.  Analysis of repeated biopsy results within 1 year after a noncancer diagnosis.

Authors:  G J O'dowd; M C Miller; R Orozco; R W Veltri
Journal:  Urology       Date:  2000-04       Impact factor: 2.649

3.  Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.

Authors:  B Djavan; A Zlotta; M Remzi; K Ghawidel; A Basharkhah; C C Schulman; M Marberger
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

4.  Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer.

Authors:  S R Potter; W Horniger; M Tinzl; G Bartsch; A W Partin
Journal:  Urology       Date:  2001-06       Impact factor: 2.649

5.  Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?

Authors:  B Djavan; V Ravery; A Zlotta; P Dobronski; M Dobrovits; M Fakhari; C Seitz; M Susani; A Borkowski; L Boccon-Gibod; C C Schulman; M Marberger
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

6.  Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy.

Authors:  S Park; K Shinohara; G D Grossfeld; P R Carroll
Journal:  J Urol       Date:  2001-05       Impact factor: 7.450

7.  Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores.

Authors:  D J Grossklaus; C S Coffey; S B Shappell; G S Jack; M S Cookson
Journal:  BJU Int       Date:  2001-11       Impact factor: 5.588

8.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

9.  The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.

Authors:  M Ohori; T M Wheeler; P T Scardino
Journal:  Cancer       Date:  1994-07-01       Impact factor: 6.860

10.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.

Authors:  M Ohori; T M Wheeler; J K Dunn; T A Stamey; P T Scardino
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

View more
  11 in total

1.  Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies.

Authors:  Bumsoo Park; Seong-Soo Jeon; Sung-Ho Ju; Byong-Chang Jeong; Seong-Il Seo; Hyun-Moo Lee; Han-Yong Choi
Journal:  Asian J Androl       Date:  2012-12-31       Impact factor: 3.285

2.  Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols.

Authors:  Christopher B Anderson; Amy L Tin; Daniel D Sjoberg; John P Mulhall; Jaspreet Sandhu; Karim Touijer; Vincent P Laudone; James A Eastham; Peter T Scardino; Behfar Ehdaie
Journal:  BJU Int       Date:  2015-07-20       Impact factor: 5.588

3.  Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database.

Authors:  Ryan P Kopp; Sean P Stroup; Florian R Schroeck; Stephen J Freedland; Frederick Millard; Martha K Terris; William J Aronson; Joseph C Presti; Christopher L Amling; Christopher J Kane
Journal:  J Urol       Date:  2012-04-11       Impact factor: 7.450

4.  Prebiopsy MRI and MRI-ultrasound Fusion-targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies.

Authors:  Neil Mendhiratta; Xiaosong Meng; Andrew B Rosenkrantz; James S Wysock; Michael Fenstermaker; Richard Huang; Fang-Ming Deng; Jonathan Melamed; Ming Zhou; William C Huang; Herbert Lepor; Samir S Taneja
Journal:  Urology       Date:  2015-08-31       Impact factor: 2.649

5.  Clinicopathologic differences between prostate cancers detected during initial and repeat transrectal ultrasound-guided biopsy in Korea.

Authors:  Dong Jin Park; Ki Ho Kim; Tae Gwon Kwon; Chun Ii Kim; Cheol Hee Park; Jae Shin Park; Duck Youn Kim; Jae Soo Kim; Ki Hak Moon; Kyung Seop Lee
Journal:  Korean J Urol       Date:  2014-11-10

6.  Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada.

Authors:  Catalina Vasquez; Michael Kolinsky; Rume Djebah; Maxwell Uhlich; Bryan Donnelly; Adrian S Fairey; Eric Hyndman; Nawaid Usmani; Jackson Wu; Peter Venner; Dean Ruether; Gerald Todd; Michael Chetner; R Trafford Crump; Perrin H Beatty; John D Lewis
Journal:  BMJ Open       Date:  2020-10-16       Impact factor: 2.692

7.  Are more low-risk prostate cancers detected by repeated biopsy? A retrospective pilot study.

Authors:  Seung Je Lee; Insang Hwang; Eu Chang Hwang; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park
Journal:  Korean J Urol       Date:  2013-06-12

8.  Differences in Postoperative Pathological Outcomes between Prostate Cancers Diagnosed at Initial and Repeat Biopsy.

Authors:  In Ho Khang; Yun Beom Kim; Seung Ok Yang; Jeong Ki Lee; Tae Young Jung
Journal:  Korean J Urol       Date:  2012-08-16

9.  Characterization of prostate cancer detected at repeat biopsy.

Authors:  Takeshi Yuasa; Norihiko Tsuchiya; Teruaki Kumazawa; Takamitsu Inoue; Shintaro Narita; Mitsuru Saito; Yohei Horikawa; Shigeru Satoh; Tomonori Habuchi
Journal:  BMC Urol       Date:  2008-11-10       Impact factor: 2.264

10.  A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA 'grey zone'.

Authors:  Jennifer Creed; Laurence Klotz; Andrew Harbottle; Andrea Maggrah; Brian Reguly; Anne George; Vincent Gnanapragasm
Journal:  World J Urol       Date:  2017-12-16       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.